

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES

VACCINES FOR CHILDREN PROGRAM

VACCINES TO PREVENT HUMAN PAPILLOMAVIRUS

The purpose of this resolution is to update the resolution to include use of a 9-valent HPV vaccine that was recently licensed for use and to clarify the schedule and timing of vaccine intervals.

VFC Resolution 10/11-1 is repealed and replaced by the following:

Eligible Groups

Gender and Age	Bivalent HPV vaccine (HPV2)	Quadrivalent HPV vaccine (HPV4)	9-valent HPV vaccine (HPV9)
Females, 9 through 18 years	Eligible	Eligible	Eligible
Males, 9 through 18 years	Not eligible	Eligible	Eligible

Recommended schedule and intervals

ACIP recommends that routine HPV vaccination be initiated at age 11 or 12 years. The vaccination series can be started beginning at age 9 years. Vaccination is recommended for females and males 13 through 18 years of age who have not been previously vaccinated or who have not completed the full series.

HPV2, HPV4 and HPV9 are each administered in a 3-dose schedule. The second dose is administered at least 1 to 2 months after the first dose and the third dose at least 6 months after the first dose.

If vaccination providers do not know, or do not have available the HPV vaccine product previously administered, or are in clinical settings transitioning to HPV9, for protection against HPV 16 and 18, any available HPV vaccine product may be used to continue or complete the series for females; HPV9 or HPV4 may be used to continue or complete the series for males.

Interrupted vaccination schedule and minimum intervals

If the vaccine schedule is interrupted, the vaccine series does not need to be restarted. The first and second doses should be separated by an interval of least four weeks. The second and third doses should be separated by an interval of at least 12 weeks, with a minimum interval of 24 weeks between the first and third doses.

Recommended dosage

Refer to product package inserts.

Precautions and contraindications

Precautions and contraindications can be found in the package inserts available at:
<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833>.

[If an ACIP recommendation regarding the human papillomavirus vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]

Adopted and Effective: February 26, 2015

This document can be found on the CDC website at:
<http://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html>